Transgenic Tau Models
Test potential therapeutics for Alzheimer’s disease and other Tauopathies in mouse models with Tau deposition and the downstream pathological events
The histopathological hallmarks of Alzheimer’s disease (AD) are extracellular plaques composed of amyloid beta (Aβ) and intracellular inclusions of the protein Tau (neurofibrillary tangles). Tau is encoded by the microtubule-associated protein tau (MAPT) gene. Tau pathology in AD and other Tauopathies such as frontotemporal dementia (FTD) is strongly associated with neurodegeneration and clinical symptoms.
Models overexpressing human Tau with disease associated MAPT mutations display abundant tau pathology, neuroinflammation, neurodegeneration, and behavioural impairments; making them ideal models to test therapeutic interventions for AD and other tauopathies.
InnoSer offers expert guidance and collaborative approach on selecting the best model for your research, as the models we offer present varying degrees of neurofibrillary tangles, neuroinflammation, neurodegeneration, and behavioural deficits.
Transgenic amyloid models that InnoSer offers:
- P301S (PS19)
- TauP301L (JNPL3)
- Tau seeding models (e.g., in PS19, hTau)
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs
Test the efficacy of your treatments in the following behavioural tests:
- Grip strength test
- CatWalk gait analysis
- Rotarod test
- Nesting test
- MSD: Plasma, CSF, and brain (pTau, cytokines, NF-L)
- (Digital) histopathology
- Immunohistochemistry (e.g., pTau, neuroinflammation, neurodegeneration)
- Immunofluorescence and FISH
Transgenic P301S (PS19) mice show Tau pathology (AT8; phosphorylated Tau) at 8 months of age
Transgenic P301S (PS19) have astro- and microgliosis at 8 months of age.
Thy1-P301L mice show subtle, but significant changes in gait and footprint size on the Catwalk test indicating fine motor skills deficit at 6 months of age; by 10 months or older, these mice show profound motor function deficits
The CatWalk XT (Noldus IT, The Netherlands) is a gait analysis system for quantitative assessment of gait and locomotion in mice. It is the most sophisticated system for the quantification of a wide range of parameters related to footprints and gait in unforced moving animals.
Thy1 (P301S) mice show a progressive decrease in grip strength from 14 weeks of age onwards.
The Grip Strength test assesses neuromuscular function by measuring the peak force a mouse can apply by grasping a bar connected to a force meter. Five trials with front paws are followed by five trials with front and hind paws combined. The median of these five trials is used as a measure of grip strength. The grip strength test is used in Tau transgenic models to longitudinally follow the build-up of toxic Tau protein in the brain stem and spinal cord.
Related Alzheimer’s disease model options
Neurology Platform Overview
Transgenic Amyloid Models
InnoSer offers preclinical research services with several different transgenic amyloid models, which recapitulate the plaque pathology of AD.
Tau Seeding Model
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know